Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495000 | 1.00 | ALDH1A1 (0.76) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| 3,6 Dichloromethoxybenzoic Acid SCHEMBL29539000 | 0.86 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| 3,6 Dichloromethoxybenzoic Acid SCHEMBL18336 | 0.86 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| 3,6 Dichloromethoxybenzoic Acid SCHEMBL1932787 | 0.86 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| SCHEMBL14416606 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| SCHEMBL11165767 | 0.85 | ALDH1A1 (0.76) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| 3,6 Dichloromethoxybenzoic Acid SCHEMBL1702321 | 0.85 | ALDH1A1 (0.96) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| 3,6 Dichloromethoxybenzoic Acid SCHEMBL1682195 | 0.85 | ALDH1A1 (0.96) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| 3,6 Dichloromethoxybenzoic Acid SCHEMBL2369132 | 0.85 | ALDH1A1 (0.96) | ALDH1A1KDM4EHSD17B10CA12CA1 | |
| SCHEMBL3057430 | 0.85 | ALDH1A1 (0.63) | ALDH1A1KDM4EHSD17B10CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157284-A1 | HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA | BASF CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-20230148590-A1 | Aqueous Formulations of Dicamba | BASF CORPORATION | 2023-05-18 | — | — | US | claimed |
| EP-4132274-A1 | HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA | BASF Corporation (US) | 2023-02-15 | — | — | EP | claimed |
| EP-4125365-A1 | AQUEOUS FORMULATIONS OF DICAMBA | BASF Corporation (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115426880-A | Aqueous formulations of dicamba | 巴斯夫公司 | 2022-12-02 | — | — | CN | claimed |
| CN-115361868-A | High-load solution concentrates of dicamba | 巴斯夫公司 | 2022-11-18 | — | — | CN | claimed |
| WO-2021198458-A1 | AQUEOUS FORMULATIONS OF DICAMBA | BASF CORPORATION (US) | 2021-10-07 | — | — | WO | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-1193261-A1 | New thiadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0810207-A1 | Bis-ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-03 | — | — | EP | disclosed |
| EP-0004831-B1 | 2,6-DIALKOXYBENZAMIDES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS AND THESE COMPOUNDS FOR USE IN THE TREATMENT OF PSYCHOTIC DISORDES | Astra Läkemedel Aktiebolag (SE) | 1983-02-16 | — | — | EP | disclosed |
| US-4232037-A | 2,6-Dialkoxybenzamides, intermediates, pharamaceutical compositions and methods for treatment of psychotic disorders | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1980-11-04 | — | — | US | disclosed |
| EP-0004831-A2 | 2,6-Dialkoxybenzamides, process for their preparation, compositions and these compounds for use in the treatment of psychotic disordes | Astra Läkemedel Aktiebolag (SE) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | ALDH1A1 239/4885KDM4E 1290/4885HSD17B10 402/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | ALDH1A1 1973/4885KDM4E 2023/4885HSD17B10 713/4885 |
| US-20230148590-A1 | Aqueous Formulations of Dicamba | BOLA2; BOLA2B, CIP2A, AQP1 | ALDH1A1 3828/4885KDM4E 3477/4885HSD17B10 1656/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | ALDH1A1 1296/4885KDM4E 270/4885HSD17B10 2588/4885 |
| US-20230157284-A1 | HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA | PDHB, PDHA1, LDHB | ALDH1A1 1726/4885KDM4E 1320/4885HSD17B10 178/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | ALDH1A1 239/4885KDM4E 1290/4885HSD17B10 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.